Mark Lampert‘s Biotechnology Value Fund reported raising its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to 3.11 million shares, which account for 17.9% of the company’s outstanding stock, via a newly-amended 13G filing released by the Securities and Exchange Commission. Previously, the fund held 1.78 million shares or 12.3% of Xenon’s outstanding stock, according to its 13F filing for the June 30 reporting period.
As the name denotes it, Xenon Pharmaceuticals is a clinical stage biopharmaceutical company that develops various therapeutics for orphan indications. Recently, the company made a $30 million public offering of common shares, priced at $7.50 per share. Year-to-date, Xenon Pharmaceuticals’ stock is down by 4.48%. In its latest financial report, for the second quarter of 2016, the company disclosed revenue of $0.4 million and a basic loss per share of $0.42, compared to a revenue of $4.04 million and earnings per share of $0.08, for the corresponding period of the prior year.
wavebreakmedia/Shutterstock.com
Among the hedge funds from Insider Monkey’s database, seven were long Xenon Pharmaceuticals (NASDAQ:XENE) at the end of June, down from eight a quarter earlier. Some of the bullish investors contained Steve Cohen’s Point72 Asset Management, with a position valued at $2.12 million, and Jim Simons’ Renaissance Technologies, which held a position worth around $286,000.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Biotechnology Value Trading Fund OS | 0 | 262,664 | 0 | 262,664 | 262,664 | 1.5% |
| BVF Partners OS Ltd | 0 | 262,664 | 0 | 262,664 | 262,664 | 1.5% |
| BVF Partners | 0 | 3,108,905 | 0 | 3,108,905 | 3,108,905 | 17.9% |
| BVF Inc | 0 | 3,108,905 | 0 | 3,108,905 | 3,108,905 | 17.9% |
| Mark N. Lampert | 0 | 3,108,905 | 0 | 3,108,905 | 3,108,905 | 17.9% |
Page 1 of 10 – SEC Filing
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
| Xenon Pharmaceuticals Inc. |
| (Name of Issuer) |
| Common Shares, no par value per share |
| (Title of Class of Securities) |
| 98420N 10 5 |
| (CUSIP Number) |
| September 8, 2016 |
| (Date of Event Which Requires Filing of this Statement) |
| o | Rule 13d-1(b) |
| x | Rule 13d-1(c) |
| o | Rule 13d-1(d) |
_______________
DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks
If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.
Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Silicon Graphics International Corp (SGI): Billionaire Chuck Royce Slashes...
Chart Industries Inc (GTLS): Pzena Investment Management Lowers Its Stake
Orbcomm Inc. (ORBC): Raging Capital Management Decreases Stake
Innoviva Inc. (INVA): Billionaire Seth Klarman’s Baupost Group Reduces...Pbf Energy Inc. (PBF): Billionaire Seth Klarman’s Baupost Group Raises...Moelis & Co (MC): Billionaire Chuck Royce’s Royce & Associates...
